Denali Therapeutics (4DN) Stock Forecast & Price Target

Compare

7 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4DN Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Denali

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4DN Stock 12 Month Forecast

Average Price Target

€26.64

▲(67.54% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is €26.64 with a high forecast of €31.80 and a low forecast of €22.34. The average price target represents a 67.54% change from the last price of €15.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","21":"€21","32":"€32","15.5":"€15.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.79519076,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€31.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.63921388,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.34256648,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€22.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.5,21,26.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,17.12270698153846,18.345413963076922,19.568120944615384,20.790827926153845,22.013534907692307,23.23624188923077,24.45894887076923,25.681655852307692,26.904362833846154,28.127069815384615,29.349776796923077,30.57248377846154,{"y":31.79519076,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,16.726093375384615,17.55218675076923,18.378280126153847,19.204373501538463,20.03046687692308,20.856560252307695,21.682653627692307,22.508747003076923,23.33484037846154,24.16093375384615,24.987027129230768,25.813120504615384,{"y":26.63921388,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.9,16.395582036923077,16.891164073846156,17.38674611076923,17.882328147692306,18.377910184615384,18.873492221538463,19.369074258461538,19.864656295384613,20.36023833230769,20.85582036923077,21.351402406153845,21.84698444307692,{"y":22.34256648,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.605,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.515,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.945,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.115,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€31.80

Average Price Target€26.64

Lowest Price Target€22.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Chico

Wedbush

€26.4→€25.55

Buy

60.70%

Upside

Reiterated

12/11/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Myles Minter

William Blair

―

Buy

―

Reiterated

12/05/25

Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating

Paul Matteis

Stifel Nicolaus

€31.51

Buy

98.20%

Upside

Reiterated

12/05/25

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Tazeen Ahmad

Bank of America Securities

€22.14→€24.7

Buy

55.35%

Upside

Reiterated

12/04/25

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)

Thomas Shrader

BTIG

€27.26

Buy

71.42%

Upside

Reiterated

12/04/25

Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs

Andrew Fein

H.C. Wainwright

€27.26

Buy

71.42%

Upside

Reiterated

12/03/25

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Mayank Mamtani

B. Riley Securities

€25.55

Buy

60.70%

Upside

Reiterated

12/01/25

B. Riley Securities Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

€29.81

Buy

87.49%

Upside

Reiterated

11/10/25

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/06/25

Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy RatingWe remain optimistic for approval of '310 after the recent PDUFA date extension, and note the company could have 2 products on the mkt over the next few yrs after AA alignment for '126 in MPS IIIA. Denali also has several P.C. TV programs near the clinic. We see DNLI shares as undervalued for the potential of the TV platform.

Jessica Fye

J.P. Morgan

€22.14

Buy

39.28%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Sean Laaman

Morgan Stanley

€28.11→€25.55

Buy

60.70%

Upside

Reiterated

08/18/25

Denali Therapeutics (DNLI) Receives a Buy from Morgan StanleyDNLI.O Denali Therapeutics Inc Overweight with price target change from 33.00 to 30.00.

Marc Goodman

Leerink Partners

€34.07

Buy

114.27%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Joel Beatty

Robert W. Baird

€25.55→€24.7

Buy

55.35%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $29 from $30 at BairdDenali Therapeutics price target lowered to $29 from $30 at Baird

David Hoang

Deutsche Bank

€26.4

Buy

66.06%

Upside

Initiated

02/11/25

Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Chico

Wedbush

€26.4→€25.55

Buy

60.70%

Upside

Reiterated

12/11/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Myles Minter

William Blair

―

Buy

―

Reiterated

12/05/25

Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating

Paul Matteis

Stifel Nicolaus

€31.51

Buy

98.20%

Upside

Reiterated

12/05/25

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

Tazeen Ahmad

Bank of America Securities

€22.14→€24.7

Buy

55.35%

Upside

Reiterated

12/04/25

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)

Thomas Shrader

BTIG

€27.26

Buy

71.42%

Upside

Reiterated

12/04/25

Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs

Andrew Fein

H.C. Wainwright

€27.26

Buy

71.42%

Upside

Reiterated

12/03/25

H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Mayank Mamtani

B. Riley Securities

€25.55

Buy

60.70%

Upside

Reiterated

12/01/25

B. Riley Securities Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

€29.81

Buy

87.49%

Upside

Reiterated

11/10/25

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/06/25

Jessica Fye

J.P. Morgan

€22.14

Buy

39.28%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Sean Laaman

Morgan Stanley

€28.11→€25.55

Buy

60.70%

Upside

Reiterated

08/18/25

Denali Therapeutics (DNLI) Receives a Buy from Morgan StanleyDNLI.O Denali Therapeutics Inc Overweight with price target change from 33.00 to 30.00.

Marc Goodman

Leerink Partners

€34.07

Buy

114.27%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Joel Beatty

Robert W. Baird

€25.55→€24.7

Buy

55.35%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $29 from $30 at BairdDenali Therapeutics price target lowered to $29 from $30 at Baird

David Hoang

Deutsche Bank

€26.4

Buy

66.06%

Upside

Initiated

02/11/25

Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

1 Month

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.57%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.57% per trade.

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+13.06%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +13.06% per trade.

1 Year

Laura ChicoWedbush

Success Rate

9/18 ratings generated profit

Average Return

+13.89%

reiterated a buy rating 18 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.89% per trade.

2 Years

xxx

Success Rate

8/20 ratings generated profit

Average Return

-3.94%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -3.94% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4DN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4DN has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4DN average Analyst price target in the past 3 months is 26.64.

Each month's total comprises the sum of three months' worth of ratings.

4DN Financial Forecast

4DN Earnings Forecast

Next quarter’s earnings estimate for 4DN is -€0.64 with a range of -€0.79 to -€0.53. The previous quarter’s EPS was -€0.63. 4DN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 4DN has Performed in-line its overall industry.

4DN Sales Forecast

Next quarter’s sales forecast for 4DN is €2.63M with a range of €0.00 to €21.36M. The previous quarter’s sales results were €0.00. 4DN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 4DN has Performed in-line its overall industry.

4DN Stock Forecast FAQ

What is DE:4DN’s average 12-month price target, according to analysts?

Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 26.64.

What is DE:4DN’s upside potential, based on the analysts’ average price target?

Denali Therapeutics has 67.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Denali Therapeutics a Buy, Sell or Hold?

Denali Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Denali Therapeutics’s share price target?

The average share price target for Denali Therapeutics is 26.64. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €31.80 ,and the lowest forecast is €22.34. The average share price target represents 67.54% Increase from the current price of €15.9.

What do analysts say about Denali Therapeutics?

Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Denali Therapeutics?

To buy shares of DE:4DN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Denali Therapeutics (4DN) Stock Forecast & Price Target

4DN Analyst Ratings

4DN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Denali Therapeutics

4DN Analyst Recommendation Trends

4DN Financial Forecast

4DN Earnings Forecast

4DN Sales Forecast

4DN Stock Forecast FAQ

Detailed List of Analyst Forecasts